By Counterforce Health Team in Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) —

The Complete Checklist to Get Rylaze Covered by Humana in Michigan: Prior Authorization, Appeals, and Required Documentation

Answer Box: Getting Rylaze Covered by Humana in Michigan

Who qualifies: Patients with ALL/LBL who developed hypersensitivity to E. coli asparaginase (Oncaspar, Elspar, Asparlas) need documented allergic reactions and failed prior therapy.

Fastest approval path: Submit prior authorization through Humana's provider portal with comprehensive hypersensitivity documentation, medical necessity letter, and current treatment protocol. Contact CenterWell Specialty Pharmacy at 1-844-486-2668 for coordination.

First step today: Gather all records of your E. coli asparaginase reaction (clinical notes, ER records, intervention details) and request your oncologist submit the PA with complete documentation package.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding and Billing Information
  5. Documentation Packet Essentials
  6. Submission Process
  7. Specialty Pharmacy Coordination
  8. After Submission: Tracking Your Request
  9. Common Denial Reasons & How to Avoid Them
  10. Appeals Process in Michigan
  11. Quick Reference Checklist

Who Should Use This Checklist

This guide is designed for patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who have experienced hypersensitivity reactions to E. coli-derived asparaginase products and need Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) coverage through Humana in Michigan.

Expected outcome: With proper documentation, most medically necessary Rylaze requests are approved within 15-30 days. Humana's Medicare Advantage plans have a relatively low prior authorization denial rate of approximately 3.5%, but specialty oncology medications require thorough clinical justification.

You'll need this checklist if:

  • You've had allergic reactions to Oncaspar, Elspar, or Asparlas
  • Your oncologist is prescribing Rylaze as part of multi-agent chemotherapy
  • You have active Humana coverage (Medicare Advantage, commercial, or Medicaid plans)
  • You're facing a prior authorization requirement or denial

Member & Plan Basics

Coverage Requirements

Active enrollment verification: Confirm your Humana coverage is active and includes prescription drug benefits. For Medicare Advantage plans, Rylaze is typically covered under Part B as a chemotherapy drug when administered in clinical settings.

Plan type considerations:

  • Medicare Advantage: Prior authorization required; covered under medical benefits
  • Commercial plans: PA requirements vary; check your specific formulary
  • Medicaid managed care: Coverage through Michigan's Healthy Michigan program
Tip: Verify your current deductible status and any specialty drug copayment requirements before starting the approval process.

Authorization Requirements

Humana requires prior authorization for Rylaze due to its high cost (approximately $5,837 per unit) and limited distribution status. The medication must be prescribed by an oncologist or hematologist and dispensed through approved specialty pharmacies.

Clinical Criteria Requirements

Primary Indication

Rylaze is approved for patients ≥1 month old with ALL or LBL as a component of multi-agent chemotherapy who have developed hypersensitivity to E. coli-derived asparaginase.

Step Therapy Documentation

Required evidence of E. coli asparaginase failure:

  • Documented hypersensitivity reaction to pegaspargase (Oncaspar), native E. coli asparaginase (Elspar), or calaspargase pegol (Asparlas)
  • Clinical notes describing specific symptoms: anaphylaxis, bronchospasm, hypotension, angioedema, rash, or urticaria
  • Grade II or higher adverse events per CTCAE criteria
  • Medical intervention records (epinephrine, steroids, hospitalization)

Dosing and Duration

Standard dosing: 25 mg/m² intramuscularly every 48 hours when replacing long-acting asparaginase products. Your treatment plan must specify:

  • Body surface area calculation
  • Planned number of doses
  • Integration with multi-agent chemotherapy protocol
  • Monitoring schedule for serum asparaginase activity

Coding and Billing Information

Essential Codes

Code Type Code Description Notes
HCPCS J-Code J9021 Injection, asparaginase, recombinant, (rylaze), 0.1 mg Permanent code for 2025
NDC Numbers 68727-900-03 (10-digit)
68727-0900-03 (11-digit)		 Carton containing 3 vials Both formats accepted
ICD-10 Diagnosis C91.00-C91.02 Acute lymphoblastic leukemia Primary diagnosis
ICD-10 Diagnosis C83.50-C83.59 Lymphoblastic lymphoma Alternative primary

Billing Units

Rylaze is supplied as 10 mg/0.5 mL single-dose vials. For billing purposes, the unit of coverage is typically 1 mg per unit. Ensure your provider uses the correct NDC format required by your specific Humana plan.

Documentation Packet Essentials

Medical Necessity Letter Components

Your oncologist's letter must include:

Patient identification:

  • Full name, date of birth, Humana member ID
  • Current diagnosis with ICD-10 codes
  • Treating physician credentials and specialty

Hypersensitivity documentation:

  • Detailed description of E. coli asparaginase reaction
  • Date, symptoms, severity grading (CTCAE)
  • Medical interventions required
  • Supporting lab values if available

Clinical justification:

  • Reference to NCCN guidelines supporting Erwinia asparaginase for hypersensitive patients
  • Explanation of immediate health risks from treatment delays
  • Statement that no equally effective alternatives exist
  • Current disease status and treatment urgency

Treatment plan:

  • Proposed Rylaze dosing schedule
  • Multi-agent chemotherapy protocol details
  • Monitoring plan including serum asparaginase activity testing
  • Expected treatment duration

Required Attachments

  • Complete medical records documenting hypersensitivity reaction
  • Emergency department or hospitalization records (if applicable)
  • Laboratory results and imaging studies
  • Previous treatment history and outcomes
  • Current oncology consultation notes
  • Pathology reports confirming ALL/LBL diagnosis

Submission Process

Preferred Submission Method

Submit through Humana's provider portal for fastest processing. The online system allows real-time status tracking and reduces processing delays.

Portal submission steps:

  1. Log into provider portal with credentials
  2. Navigate to Prior Authorization section
  3. Select "Pharmacy" or "Medical" based on administration setting
  4. Complete all required fields (verify current form version)
  5. Upload all supporting documentation
  6. Submit and record confirmation number

Common Submission Errors

Fields that frequently cause rejections:

  • Incomplete member identification information
  • Missing or incorrect diagnosis codes
  • Inadequate hypersensitivity reaction documentation
  • Unsigned medical necessity letters
  • Wrong NDC or HCPCS codes
Note: Double-check all form fields before submission. Incomplete applications automatically trigger denials and restart the review timeline.

Specialty Pharmacy Coordination

Preferred Network Pharmacy

CenterWell Specialty Pharmacy is Humana's preferred vendor for limited distribution oncology medications like Rylaze in Michigan.

Contact information:

  • Phone: 1-844-486-2668 (TTY: 711)
  • Hours: Monday-Friday 8 AM-8 PM CST; Saturday 8 AM-6 PM CST

Coordination Steps

  1. Provider e-prescribes to CenterWell Specialty Pharmacy
  2. CenterWell initiates prior authorization process with Humana
  3. Patient enrollment in specialty pharmacy services
  4. Shipment coordination once approval obtained
  5. Ongoing refill management and clinical support
Important: Using non-network pharmacies will result in full out-of-pocket costs, even with prior authorization approval.

After Submission: Tracking Your Request

Timeline Expectations

  • Standard review: 15-30 calendar days
  • Expedited review: 72 hours (requires physician attestation of urgency)
  • Peer-to-peer review: Additional 5-7 days if requested

Status Monitoring

Track your request:

  • Provider portal status updates
  • Humana member services: 1-800-Humana (1-800-486-2621)
  • CenterWell Specialty Pharmacy coordination team

Documentation to maintain:

  • Confirmation numbers from all submissions
  • Date/time stamps of phone calls
  • Names of representatives contacted
  • Any additional information requested

Common Denial Reasons & How to Avoid Them

Denial Reason Prevention Strategy Required Documentation
Insufficient hypersensitivity evidence Include detailed clinical notes with specific symptoms, dates, and interventions ER records, physician notes, intervention documentation
Missing step therapy documentation Provide complete records of E. coli asparaginase trials and failures Treatment history, adverse event reports, CTCAE grading
Incomplete medical necessity Submit comprehensive letter addressing all clinical criteria Oncologist letter, treatment protocol, monitoring plan
Coding errors Verify current HCPCS, NDC, and ICD-10 codes before submission Updated coding references, billing department review
Wrong pharmacy network Coordinate exclusively with CenterWell Specialty Pharmacy Network verification, proper e-prescribing

Appeals Process in Michigan

Internal Appeals (First Level)

If your initial request is denied, you have 65 days to file an internal appeal with Humana.

Required elements:

  • Written appeal request
  • Copy of original denial letter
  • Additional supporting documentation
  • Updated medical necessity letter addressing denial reasons

Michigan External Review

After exhausting Humana's internal appeals, Michigan residents can request external review through the Department of Insurance and Financial Services (DIFS).

Key details:

  • Timeline: 127 days after final internal denial
  • Standard review: 60 days maximum
  • Expedited review: 72 hours with physician urgency letter
  • Contact: Michigan DIFS at 877-999-6442

Submit external review:

  • Online External Review Request form (verify with the source linked)
  • Email, fax, or mail submission options
  • Independent Review Organization (IRO) assignment
  • Binding decision on medical necessity
From our advocates: We've seen cases where patients initially denied for Rylaze obtained approval through external review when comprehensive hypersensitivity documentation was submitted with detailed peer-reviewed evidence supporting the medical necessity. The key was demonstrating that delays in switching to Erwinia asparaginase would compromise treatment outcomes.

Quick Reference Checklist

Before You Start

  • Verify active Humana coverage with prescription benefits
  • Gather complete hypersensitivity reaction documentation
  • Confirm oncologist/hematologist is prescribing provider
  • Identify CenterWell Specialty Pharmacy as dispensing location

Clinical Documentation

  • ALL/LBL diagnosis with ICD-10 codes
  • Documented E. coli asparaginase hypersensitivity (Grade II+ CTCAE)
  • Medical intervention records (ER visits, medications given)
  • Current treatment protocol and dosing plan
  • Serum asparaginase activity monitoring schedule

Submission Package

  • Complete prior authorization form (current version)
  • Medical necessity letter on physician letterhead
  • All supporting clinical documentation
  • Correct HCPCS (J9021) and NDC codes
  • Provider signature and credentials

After Submission

  • Record confirmation number and submission date
  • Schedule follow-up for status check in 10-14 days
  • Coordinate with CenterWell for pharmacy services
  • Prepare appeal documentation if needed

Frequently Asked Questions

How long does Humana prior authorization take for Rylaze in Michigan? Standard review takes 15-30 days. Expedited review (72 hours) is available when your physician documents treatment urgency and potential harm from delays.

What if Rylaze is non-formulary on my Humana plan? Non-formulary medications can still be covered through formulary exceptions when medically necessary. The same documentation requirements apply, with additional emphasis on lack of formulary alternatives.

Can I request an expedited appeal in Michigan? Yes, both Humana internal appeals and Michigan external reviews offer expedited timelines (72 hours) when your physician provides written documentation that delays would harm your health.

Does step therapy apply if I developed hypersensitivity outside Michigan? Step therapy requirements are based on your medical history regardless of location. Documentation of hypersensitivity reactions from any provider will satisfy step therapy requirements.

What happens if CenterWell Specialty Pharmacy isn't available in my area? CenterWell provides nationwide coverage including Michigan. If there are access issues, Humana may authorize alternative specialty pharmacies, but this requires additional prior authorization.

Counterforce Health helps patients, clinicians, and specialty pharmacies get prescription drugs approved by turning insurance denials into targeted, evidence-backed appeals. Our platform streamlines the prior authorization process by identifying denial reasons and crafting point-by-point rebuttals aligned to each plan's specific requirements, pulling the right clinical evidence and citations to support medical necessity. Learn more about how Counterforce Health can help with your medication appeals.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan specifics. Always consult with your healthcare provider and insurance plan for personalized guidance. For assistance with insurance appeals and medication access, contact Michigan DIFS at 877-999-6442 or visit their website for official forms and procedures.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.